secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001725160-25-000013
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis reports azenosertib ORR 34.9% in Cyclin E1+ PROC; FDA aligned on DENALI Part 2 for accelerated approval path
--------------------------------------------------------------------------------

- DENALI Part 1b in Cyclin E1+ PROC achieved 34.9% ORR (response-evaluable n=43) and ~5.5 months median DOR; ITT ORR 31.3%.
- FDA aligned on seamless DENALI Part 2 design; enrollment to begin 1H 2025 with topline data by year-end 2026; potential accelerated approval.
- MAMMOTH monotherapy in Cyclin E1+ patients at 400mg QD 5:2 showed 31.3% ORR (n=16); safety profile well-characterized with low discontinuation rate.
- Company discontinues ZN-c3-016 (BRAF CRC expansion) due to resource prioritization; no further development of niraparib combination.
- Corporate restructuring extended cash runway into late 2027, beyond expected DENALI Part 2 data readout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000013/0001725160-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000013/zntl-20250129.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer